Zidovudine (ZDV) appears to prevent selection of K65R and L74V, mutations normally selected by Abacavir (ABC) mono- or combination therapies not containing ZDV

Adherence to HAART in children: results from a questionnaire study of children in PENTA 5 trial

96 week follow-up of the PENTA 5 trial; comparing ZDV+3TC, ZDV+ABC and 3TC+ABC with or without NFV in ART naive children

PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection.

Biphasic decay of cell-associated HIV-1 DNA in HIV-1 infected children on antiretroviral therapy

Impact of HIV-1 subtypes on virologic response and emergence of drug resistance

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral naïve HIV-1 infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)

Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

Difficulties in achieving suppression of viral replication in vertically HIV-1 infected infants early treated with d4T+ddI+NFV : The PENTA 7 Study.

TREC Response to Antiretroviral Therapy in HIV-infected Children in the PENTA 5 Trial

The Impact of HIV-1 Subtypes on Virological Response and Emergence of Resistance in the PENTA 5 Trial